Clinical trials: Type 1 Diabetes Mellitus With Artificial Pancreas Device
Type 1 Diabetes Mellitus
Feasibility of a Decision Support System to Reduce Glucose Variability in Subject With T1DM
The purpose of this study is to demonstrate the safety and feasibility of a decision support system aimed at reducing glucose variability in T1DM patient using an insulin pump.
- Trial name
- NCT02558491
- Testing
- Decision Support System, Usual Care
- Where
- United States
- Volunteers
- 33 people
- Sponsor
- Daniel Chernavvsky, MD
Type 1 Diabetes
Closed-Loop Insulin Delivery During Pregnancy (IADIABENCEINTE)
The imbalance of diabetes is associated with an increased risk of maternal and fetal complications. In women, it can cause abortion, hypertension, preeclampsia, and obstructed labor; in the fetus, it increases the risk of many…
- Trial name
- IADIABENCEIN (NCT05661149)
- Testing
- Hybrid closed loop insulin delivery systems
- Where
- France
- Volunteers
- 14 people
- Sponsor
- Centre Hospitalier Sud Francilien
Diabetes Mellitus, Type 1
An Outpatient Study of Automated Blood Glucose Control With an Insulin-Only Bionic Pancreas
This is an open-label, non-randomized, pilot study to determine the safety and feasibility of the insulin-only bionic pancreas.
- Trial name
- NCT02536950
- Testing
- Fixed set point, Variable set point
- Where
- United States
- Volunteers
- 16 people
- Sponsor
- Bruce A. Buckingham
Type 1 Diabetes
Liraglutide Versus Insulin Mono-therapy in the Closed Loop Setting
Hypothesis: In type 1 diabetes mellitus, in the setting of a closed loop glucose control system: adjunctive therapy with Liraglutide will afford better post-prandial glycemic excursions than insulin mono-therapy.
- Trial name
- NCT01755416
- Testing
- Closed loop with sensor and Insulin, Closed loop with sensor, Insulin and Liraglutide
- Where
- United States
- Volunteers
- 18 people
- Sponsor
- Albert Einstein College of Medicine
Type1 Diabetes Mellitus
Insulet Artificial Pancreas Free-Living IDE3
Subjects will undergo a 7±1 day outpatient, standard therapy phase during which sensor and insulin data will be collected. Subjects or their caregivers will manage their diabetes at home per their usual routine using the study…
- Trial name
- NCT03216460
- Testing
- Insulet automated glucose control system
- Where
- 3 sites in United States
- Volunteers
- 120 people
- Sponsor
- Insulet Corporation
Diabetes Mellitus, Type 1
Full Day and Night Closed-Loop With DiAs Platform
The overall aim of this proposed research is to determine the safety, feasibility and efficacy of the Diabetes Assistant (DiAs) controller in day and night closed-loop control in children and adolescents with type 1 diabetes over…
- Trial name
- NCT02147860
- Testing
- Diabetes Assistant (DiAs) with USS Virginia, Sensor Augmented Pump Therapy
- Where
- 2 sites in United States
- Volunteers
- 44 people
- Sponsor
- University of Virginia
Type 1 Diabetes
Closed-loop Control of Postprandial Glucose Levels in Children and Adults With Type 1 Diabetes
Current intensive insulin therapy in T1D involves prandial insulin boluses depending on the carbohydrate content of each ingested meal.
- Trial name
- NCT02490098
- Testing
- 6-day intervention with sensor-augmented pump therapy, 6-day intervention with single-hormone closed-loop strategy, 6-day intervention with dual-hormone closed-loop strategy
- Where
- Canada
- Sponsor
- Institut de Recherches Cliniques de Montreal
Type 1 Diabetes
Dual-hormone Artificial Pancreas Versus Single-hormone Under Exercise and a Meal Challenge
The present clinical trial aims to examine alternative strategies for preventing/mitigating hypoglycemic events among adults with type 1 diabetes utilizing a highly personalized control system.
- Trial name
- TAILOR/3 (NCT06082973)
- Testing
- Automated insulin delivery system algorithm with a dual-hormone configuration (insulin and glucagon) for glucose control, Automated insulin delivery system with a single-hormone configuration (insulin) with rescue carbohydrate recommendations for glucose control
- Where
- Spain
- Volunteers
- 15 people
- Sponsor
- Universitat Politècnica de València
Diabetes Mellitus, Diabetes Mellitus, Type 1
Home Testing of Day and Night Closed Loop With Pump Suspend Feature
The main study objective is to determine whether day and night automated closed loop glucose control combined with pump suspend feature will improve glucose control and reduce the burden of hypoglycaemia compared to sensor…
- Conditions
- Diabetes Mellitus, Diabetes Mellitus, Type 1, Glucose Metabolism Disorders, Endocrine System Diseases
- Trial name
- APCam11 (NCT02523131)
- Testing
- FlorenceM, Medtronic insulin pump 640G
- Where
- 8 sites in United States, United Kingdom
- Volunteers
- 84 people
- Sponsor
- University of Cambridge
Type 1 Diabetes
Closed-loop Control of Glucose Levels (Artificial Pancreas) for 24 Hours in Adults and Adolescents With Type 1 Diabetes
Closed-loop strategy is composed of three components: glucose sensor to read glucose levels, insulin pump to infuse insulin and a dosing mathematical algorithm to decide on the required insulin dosages based on the sensor's…
- Trial name
- NCT01754337
- Testing
- Closed-loop system
- Where
- Canada
- Volunteers
- 30 people
- Sponsor
- Institut de Recherches Cliniques de Montreal
Type 1 Diabetes Mellitus
Study Assessing an Insulin Pump-controlling Algorithm to Minimize Hypo and Hyper in Type 1 During CRC Setting
Feasibility study assessing the ability of an insulin pump-controlling algorithm to minimize hypoglycemia and hyperglycemia in patients with type 1 diabetes in a clinical research setting.
- Trial name
- NCT01638299
- Testing
- Hypo-Hyper Minimizer (HHM) System
- Where
- 2 sites in United States
- Volunteers
- 20 people, healthy volunteers welcome
- Sponsor
- Animas Corporation
Diabetes
Artificial Pancreas in Latin America
The purpose of this study is to use closed-loop systems with the algorithms designed by the University of Virginia and by the Instituto Tecnologico de Buenos Aires (ITBA)/ Universidad Nacional de La Plata (UNLP)/ Universidad…
- Trial name
- NCT02994277
- Testing
- 1° Phase: UVa algorithm 2° Phase: ITBA/UNLP algorithm
- Volunteers
- 5 people
- Sponsor
- Hospital Italiano de Buenos Aires
Type 1 Diabetes, Type 1 Diabetes Mellitus
Alleviating Carbohydrate Counting for Patients With Type 1 Diabetes Using a Novel Insulin-plus-pramlintide Artificial Pancreas
One of the main challenges in maintaining tight glucose control in a closed-loop system occurs at meal times. Amylin is a gluco-regulatory beta-cell hormone that is co-secreted with insulin in response to nutrient stimuli, and is…
- Conditions
- Type 1 Diabetes, Type 1 Diabetes Mellitus, Hyperglycemia, Postprandial
- Trial name
- NCT04163874
- Testing
- Fiasp, Pramlintide Acetate, Artificial Pancreas
- Where
- Canada
- Volunteers
- 36 people
- Sponsor
- McGill University
Type 1 Diabetes Mellitus
Reducing Risks and Improving Glucose Control During Extended Exercise in Youth With T1DM: The AP Ski Camp
The biggest challenges for glycemic control during the day time involve meals and exercise variations, which are impacted by age, fitness level, duration, intensity and history of exercise.
- Trial name
- NCT02604524
- Testing
- Closed-Loop Control, Sensor Augmented Pump Therapy
- Where
- 2 sites in United States
- Volunteers
- 32 people
- Sponsor
- Daniel Chernavvsky, MD, CRC
Type 1 Diabetes Mellitus Prone to Hypoglycemia
Artificial Pancreas With Carbohydrate Suggestion for Patients With Type 1 Diabetes Prone to Hypoglycemia
Achieving near-normoglycemia has been established as the main objective for most patients with Type 1 Diabetes (T1D). Automated insulin delivery (AID) systems, the so-called artificial pancreas (AP) or closed-loop systems, may…
- Trial name
- NCT05628662
- Testing
- Automated Insulin Delivery System (SAFE-AP)
- Where
- Spain
- Volunteers
- 12 people
- Sponsor
- Hospital Clinic of Barcelona
Type 1 Diabetes Mellitus
Feasibility Study Assessing The Ability Of An Insulin Pump-Controlling Algorithm To Minimize Hypoglycemia And Hyperglycemia In Patients With Type 1 Diabetes In A Clinical Research Setting
The purpose of this study is to evaluate the performance of an insulin pump controlling algorithm while the subject is under close medical supervision in the Clinical Research Center (CRC) setting.
- Trial name
- NCT01401751
- Testing
- Hypoglycemia-Hyperglycemia Minimizer System
- Where
- United States
- Volunteers
- 13 people, healthy volunteers welcome
- Sponsor
- Animas Corporation
Type 1 Diabetes Mellitus, Treatement by Insulin Pump
Hybrid Artificial Pancreas in Home Setting
The primary purpose of this study is the evaluate an Artificial Pancreas during 2 months in home setting in Type 1 Diabetic patients
- Trial name
- AP Hybrid (NCT02153190)
- Testing
- HYBRID, OPEN
- Where
- 3 sites in France, Italy and 1 more
- Volunteers
- 36 people
- Sponsor
- University Hospital, Montpellier
Type 1 Diabetes
Closed-loop Control of Overnight Glucose Levels in Adults and Adolescents With Type 1 Diabetes
Closed-loop strategy is composed of three components: glucose sensor to read glucose levels, insulin pump to infuse insulin and a dosing mathematical algorithm to decide on the required insulin dosages based on the sensor's…
- Trial name
- NCT01905020
- Testing
- Carbohydrate-rich meal, Exercise
- Where
- 3 sites in Canada
- Volunteers
- 28 people
- Sponsor
- Institut de Recherches Cliniques de Montreal
Type 1 Diabetes
Closed-loop Control of Overnight Glucose Levels (Artificial Pancreas) in Type 1 Diabètes Adults With Hypoglycemia Unawareness and Documented Nocturnal Hypoglycemia
Closed-loop strategy is composed of three components: glucose sensor to read glucose levels, insulin pump to infuse insulin and a dosing mathematical algorithm to decide on the required insulin dosages based on the sensor's…
- Trial name
- NCT02282254
- Testing
- Overnight intervention
- Where
- Canada
- Volunteers
- 35 people
- Sponsor
- Institut de Recherches Cliniques de Montreal
Type 1 Diabetes
Short Term Closed-loop Glucose Control in Adults With Type 1 Diabetes
The main objective of this study is to determine the feasibility, efficacy and safety of automated closed-loop glucose control in the home setting over a short term period.
- Trial name
- AP@home02 (NCT01666028)
- Testing
- FlorenceD or similar closed loop glucose control system, CSII with real-time CGM
- Where
- 3 sites in Austria, Germany and 1 more
- Volunteers
- 18 people
- Sponsor
- University of Cambridge